Andrew Hudson

617 total citations
19 papers, 436 citations indexed

About

Andrew Hudson is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Andrew Hudson has authored 19 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Andrew Hudson's work include Advanced Radiotherapy Techniques (3 papers), Melanoma and MAPK Pathways (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Andrew Hudson is often cited by papers focused on Advanced Radiotherapy Techniques (3 papers), Melanoma and MAPK Pathways (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Andrew Hudson collaborates with scholars based in United Kingdom, United States and Australia. Andrew Hudson's co-authors include John Brognard, Eleanor W. Trotter, Natalie L. Stephenson, Crispin Miller, Christopher Wirth, Lisa L. Gallegos, Frank B. Furnari, Alexandra C. Newton, Tony Hunter and Corina E. Antal and has published in prestigious journals such as Cell, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Andrew Hudson

18 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Hudson United Kingdom 8 325 98 68 54 44 19 436
Caroline Farrington United States 8 353 1.1× 111 1.1× 77 1.1× 46 0.9× 50 1.1× 10 447
Hélène Malka-Mahieu France 6 387 1.2× 136 1.4× 51 0.8× 32 0.6× 29 0.7× 10 456
Elizabeth Blackwood United States 10 351 1.1× 194 2.0× 55 0.8× 36 0.7× 52 1.2× 26 465
Jessica Oddo United States 6 457 1.4× 138 1.4× 87 1.3× 45 0.8× 30 0.7× 10 558
Amriti R. Lulla United States 11 277 0.9× 135 1.4× 97 1.4× 42 0.8× 60 1.4× 24 434
Anuj Manandhar United States 4 498 1.5× 195 2.0× 54 0.8× 54 1.0× 69 1.6× 4 604
Chung‐Min Yeh Taiwan 13 310 1.0× 117 1.2× 134 2.0× 42 0.8× 35 0.8× 32 441
Khyati N. Shah United States 9 383 1.2× 82 0.8× 79 1.2× 54 1.0× 24 0.5× 14 453
Alexander R. Chait United States 5 305 0.9× 105 1.1× 38 0.6× 33 0.6× 33 0.8× 7 507
Claire McWhirter United Kingdom 5 394 1.2× 79 0.8× 44 0.6× 45 0.8× 23 0.5× 8 478

Countries citing papers authored by Andrew Hudson

Since Specialization
Citations

This map shows the geographic impact of Andrew Hudson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Hudson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Hudson more than expected).

Fields of papers citing papers by Andrew Hudson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Hudson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Hudson. The network helps show where Andrew Hudson may publish in the future.

Co-authorship network of co-authors of Andrew Hudson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Hudson. A scholar is included among the top collaborators of Andrew Hudson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Hudson. Andrew Hudson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Bahl, Amit, Amarnath Challapalli, Balaji Venugopal, et al.. (2025). EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 1–1. 1 indexed citations
2.
Challapalli, Amarnath, Amit Bahl, Balaji Venugopal, et al.. (2025). EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 9–9. 1 indexed citations
3.
Azad, Arun, Mark Voskoboynik, Anthony M. Joshua, et al.. (2024). PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.. Journal of Clinical Oncology. 42(4_suppl). 123–123. 6 indexed citations
4.
Azad, Arun, Mark Voskoboynik, Anthony M. Joshua, et al.. (2023). Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).. Journal of Clinical Oncology. 41(6_suppl). TPS296–TPS296. 2 indexed citations
5.
Fornacon-Wood, Isabella, Clara C. Chan, N. Bayman, et al.. (2022). Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer. Frontiers in Oncology. 12. 835844–835844. 7 indexed citations
6.
Barker, Claire, Jahangeer Malik, Anna Tran, et al.. (2022). Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel. Clinical Oncology. 34(7). e291–e297. 1 indexed citations
7.
Koh, P., Andrew Hudson, W. David J. Ryder, et al.. (2021). Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clinical and Translational Radiation Oncology. 28. 24–31. 4 indexed citations
8.
Salem, Ahmed, N. Bayman, D. Cobben, et al.. (2020). Outcomes of curative-intent radiotherapy in patients with severe COPD or lung fibrosis. Lung Cancer. 139. S32–S32.
9.
Hudson, Andrew, Clara C. Chan, David Woolf, et al.. (2018). Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. Lung Cancer. 118. 139–147. 7 indexed citations
10.
Hudson, Andrew, Natalie L. Stephenson, Eleanor W. Trotter, et al.. (2018). Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases. Science Signaling. 11(526). 10 indexed citations
11.
Gupta, Avinash, Mahmood Ayub, Crispin Miller, et al.. (2017). Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling. Annals of Oncology. 28. v573–v573. 3 indexed citations
12.
Stephenson, Natalie L., Pedro Torres‐Ayuso, Anna A. Marusiak, et al.. (2016). Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene. EMBO Molecular Medicine. 8(2). 105–116. 20 indexed citations
13.
Antal, Corina E., Andrew Hudson, Emily L. Kang, et al.. (2015). Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor. Cell. 160(3). 489–502. 263 indexed citations
14.
Antal, Corina E., Andrew Hudson, Emily L. Kang, et al.. (2015). Abstract 125: Protein kinase C loss-of-function mutations in cancer reveal role as tumor suppressor. Cancer Research. 75(15_Supplement). 125–125. 2 indexed citations
15.
Hudson, Andrew, Christopher Wirth, Natalie L. Stephenson, et al.. (2015). Using Large-Scale Genomics Data to Identify Driver Mutations in Lung Cancer: Methods and Challenges. Pharmacogenomics. 16(10). 1149–1160. 11 indexed citations
16.
Hudson, Andrew, Tim Yates, Yaoyong Li, et al.. (2014). Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery. Cancer Research. 74(22). 6390–6396. 27 indexed citations
17.
Lorigan, Paul, Paolo A. Ascierto, Reinhard Dummer, et al.. (2014). Expanded access programmes: patient interests versus clinical trial integrity. The Lancet Oncology. 16(1). 15–17. 7 indexed citations
18.
Taggar, Amandeep, et al.. (2014). Outcomes From First 3 Years of Frameless Stereotactic Radiosurgery in Treating Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 90(1). S322–S322. 1 indexed citations
19.
Marusiak, Anna A., Willy Hugo, Eleanor W. Trotter, et al.. (2014). Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nature Communications. 5(1). 3901–3901. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caroline Farrington Breakdown of academic impact, for papers by Hélène Malka-Mahieu Breakdown of academic impact, for papers by Elizabeth Blackwood Breakdown of academic impact, for papers by Jessica Oddo Breakdown of academic impact, for papers by Amriti R. Lulla Breakdown of academic impact, for papers by Anuj Manandhar Breakdown of academic impact, for papers by Chung‐Min Yeh Breakdown of academic impact, for papers by Khyati N. Shah Breakdown of academic impact, for papers by Alexander R. Chait Breakdown of academic impact, for papers by Claire McWhirter
Rankless by CCL
2026